Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 17/20 | 0.60 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.56 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.56 |
| ▸ | TOP2A | P11388 | 1/20 | 0.55 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL7804066 | 0.98 | GSK3B (0.58) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL7804069 | 0.97 | GSK3B (0.57) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL1343006 | 0.90 | GSK3B (0.65) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL500863 | 0.87 | GSK3B (0.64) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL7810902 | 0.86 | GSK3B (0.48) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL9689537 | 0.85 | GSK3B (0.68) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL7812725 | 0.85 | CACNA1F (0.57) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL7816829 | 0.85 | KCNH2 (0.57) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL7813328 | 0.84 | KCNH2 (0.56) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL1345769 | 0.84 | GSK3B (0.70) | GSK3BCACNA1FPOLBMAPK1CACNA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1767536-B1 | QUINOLONECARBOXYLIC ACID COMPOUNDS, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | INST MED BIOTECHNOLOGY CAMS (CN) | 2011-06-29 | — | — | EP | disclosed |
| US-7759362-B2 | Quinolonecarboxylic acid compounds, preparation methods and pharmaceutical uses thereof | INSTITUT OF MEDICINAL BIOTECHNOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2010-07-20 | — | — | US | disclosed |
| US-20070219231-A1 | Quinolonecarboxylic acid compounds, preparation methods and pharmaceutical uses thereof | XINCHANG PHARMACEUTICAL FACTORY, ZHEJIANG MEDICINE CO. LTD. (CN) | 2007-09-20 | — | — | US | disclosed |
| EP-1767536-A1 | QUINOLONE CARBOXYLIC ACID DERIVATIVES, THEREOF PREPARATION AND USAGE | Institute of Medicinal Biotechnology, Chinese Acadamy of Medical Sciences (CN) | 2007-03-28 | — | — | EP | disclosed |
| EP-0610958-B1 | Intermediates in the preparation of 4-oxoquinoline-3-carboxylic acid derivatives | UBE INDUSTRIES (JP) | 2001-10-04 | — | — | EP | disclosed |
| EP-0878194-A1 | REMEDIES OR PREVENTIVES FOR AIDS | SANKYO COMPANY LIMITED (JP) | 1998-11-18 | — | — | EP | disclosed |
| US-5496951-A | 1-CYCLOPROPYL-6-FLUORO-8-FLUORINATED METHOXY COMPOUNDS INCLUDING BORON DIFLUORIDE CHELATE; CHEMICAL INTERMEDIATES AND ANTIBACTERIAL AGENTS | SANKYO COMPANY, LIMITED (JP) | 1996-03-05 | — | — | US | disclosed |
| US-5436367-A | 3, 4-difluorobenzoic acid derivatives | SANKO COMPANY, LIMITED (JP) | 1995-07-25 | — | — | US | disclosed |
| EP-0352123-B1 | 4-Oxoquinoline-3-carboxylic acid derivatives, their preparation and their use | UBE INDUSTRIES (JP) | 1995-01-18 | — | — | EP | disclosed |
| US-5348961-A | Antibacterial agents | SANKYO COMPANY LIMITED (JP) | 1994-09-20 | — | — | US | disclosed |
| EP-0610958-A2 | Intermediates in the preparation of 4-oxoquinoline-3-carboxylic acid derivatives | UBE INDUSTRIES, LTD. (JP) | 1994-08-17 | — | — | EP | disclosed |
| US-5073556-A | Bactericides | SANKYO COMPANY LIMITED (JP) | 1991-12-17 | — | — | US | disclosed |
| EP-0352123-A2 | 4-Oxoquinoline-3-carboxylic acid derivatives, their preparation and their use | UBE INDUSTRIES LIMITED (JP) | 1990-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219231-A1 | Quinolonecarboxylic acid compounds, preparation methods and pharmaceutical uses thereof | NQO2, ABCG2, DHX15 | GSK3B 2902/4885CACNA1F 2664/4885POLB 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.